BioClinica™, Inc., (NASDAQ: BIOC), a global provider of clinical trial
management services, today announced it has created strategic
partnerships with two clinical research organizations (CROs), Health
Sciences International, Inc., and PRL Central Laboratory Services. Both
alliances strengthen the BioClinica Certified Partner Program, a group
of VIP CRO partners chosen based on therapeutic expertise and customer
satisfaction.
“We are proud to partner with Health Sciences International and PRL
Central Laboratory Services, expanding upon the dozens of CRO
partnerships held by BioClinica worldwide”
“We are proud to partner with Health Sciences International and PRL
Central Laboratory Services, expanding upon the dozens of CRO
partnerships held by BioClinica worldwide,” said Mark Weinstein, CEO of
BioClinica, Inc. “Our newest partners demonstrate the quality and
continued growth of the BioClinica Certified Partner Program. To date
our certified partners represent a collective experience of more than
700 trials in more than 6,000 sites across 52 countries. This program is
one more way that BioClinica provides best-in-class resources for
customers.”
Connecticut-based Health Sciences International, Inc. focuses on
conducting quality phase I-IV trial research with key therapeutic areas
of focus including cardiology, vascular disorders, CNS, endocrinology
and internal medicine. The organization has participated in more than
100 clinical trials, offering clients consulting services that include
R&D expertise, statistical analysis plan development, project and data
management, quality enforcement and team building.
PRL Central Laboratory Services specializes in comprehensive diagnostic
testing, focusing on protocol requirements. For more than 30 years, the
Kansas-based research organization has worked with clinical service
providers like BioClinica, ensuring timely results and validated data
management for customers.
BioClinica announces launch of eHealth Cloud platform